Tiziana Life Sciences (TILS LN)

Tiziana Life Sciences plc, a clinical stage biotechnology company, focuses on the discovery and development of novel therapeutics for cancer in the United Kingdom. The company?s product candidate includes Milciclib that is in phase II clinical trials for thymic carcinoma in patients previously treated with chemotherapy. It also develops Foralumab, a human anti-CD3 antibody, which is in phase II clinical stage for autoimmune and inflammatory diseases, such as ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis; and Bcl-3 for use in metastasis of mammary cancers. The company is based in London, the United Kingdom. Tiziana Life Sciences plc is a subsidiary of Planwise Group Limited.